TheEdgeResearch
Home / Stocks / SPRO

Spero Therapeutics, Inc. (SPRO)

NASDAQ Healthcare Biotechnology
$1.23 ▲ +0.33%
Market Cap
$71.5M
Sector
Healthcare
Industry
Biotechnology
Beta
1.48
52-Wk Range
1.08-3.08
CEO
Esther Rajavelu
Country
US
Currency
USD

Spero Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $1.23, up 0.33% on the session, giving a market capitalisation of $71.5M. On trailing twelve-month figures it carries a trailing P/E of 4.58, a net margin of 27.8%. Its beta of 1.48 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
4.58
Price / Sales
1.30
Price / Book
1.34
EV / EBITDA
1.20
Gross margin
100.0%
Operating margin
24.7%
Net margin
27.8%
Return on equity
Debt / equity
0.05
Current ratio
10.50
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
25
IPO date
2017-11-02
Headquarters
Cambridge, MA, US
About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Comparable companies

Spero Therapeutics, Inc. is most often compared with the following Healthcare names:

ABOSACTUCGTXCRBPHURAINOIRDMCRBSEERVTGN
More research on SPRO
SPRO technical analysis SPRO TheEdge Score Compare against peers
Open full interactive analysis & DCF →